Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai agrees new licensing option for Anaeropharma cancer agent

Eisai agrees new licensing option for Anaeropharma cancer agent

29th September 2010

Eisai has agreed a collaborative deal with Anaeropharma Science over the development and licensing of a promising new anticancer agent.

The agreement sees Eisai gain right of first review to phase I clinical trial data for the Bifidobacterium longum-based treatment APS001, as well as right of first refusal for licensing the compound.

In addition, a separate agreement will see the two companies work together on further research into how characteristic features of Bifidobacterium can be used in drug delivery systems for anticancer therapies.

It is hoped that this research will deliver insight into new oncology treatment methods, a key area of therapeutic focus for both Eisai and Anaeropharma Science.

Eisai stated: "The two companies seek to make further contributions to satisfying the diverse needs of patients, their families and healthcare professionals, while increasing the benefits provided to them."

Last month, the company published new clinical trial data for the epilepsy drug perampanel, demonstrating the treatment's efficacy in reducing seizure frequency.ADNFCR-8000103-ID-800088465-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.